HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment. (Q39262034)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054560%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

title

HD-MB03 is a novel Group 3 medulloblastoma model demonstrating sensitivity to histone deacetylase inhibitor treatment (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054560%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

0 references

0 references

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054560%20AND%20SRC:MED&resulttype=core&format=json

André Saraiva Leão Antunes

10 March 2020

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054560%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Stefan M. Pfister

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054560%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

5

Marcel Kool

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054560%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

4

Andrey Korshunov

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054560%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

11

Andreas E Kulozik

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054560%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

12

Olaf Witt

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054560%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

9

Arnulf Pekrun

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054560%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

8

Ina Oehme

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054560%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

2

Marco Lodrini

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054560%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

13

Hedwig E Deubzer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054560%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

author name string

Larissa Savelyeva

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054560%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

Lena M Brueckner

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054560%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

publication date

6 October 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054560%20AND%20SRC:MED&resulttype=core&format=json

Journal of Neuro-Oncology

10 March 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054560%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

volume

110

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054560%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054560%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

page(s)

335-348

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054560%20AND%20SRC:MED&resulttype=core&format=json

describes a project that uses

10 March 2020

HD-MB03

0 references

exact match

https://scigraph.springernature.com/pub.10.1007/s11060-012-0978-1

0 references

cites work

Integrated genomics identifies five medulloblastoma subtypes with distinct genetic profiles, pathway signatures and clinicopathological features

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

Medulloblastoma comprises four distinct molecular variants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

Molecular subgroups of medulloblastoma: the current consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

HDAC5 and HDAC9 in medulloblastoma: novel markers for risk stratification and role in tumor cell growth.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

Histone deacetylase inhibitor Helminthosporium carbonum (HC)-toxin suppresses the malignant phenotype of neuroblastoma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

Histone deacetylase 8 in neuroblastoma tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

HDAC inhibitors for the treatment of cutaneous T-cell lymphomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

Pediatric phase I trial and pharmacokinetic study of vorinostat: a Children's Oncology Group phase I consortium report

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

High-throughput detection and multiplex identification of cell contaminations

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

A novel human high-risk ependymoma stem cell model reveals the differentiation-inducing potential of the histone deacetylase inhibitor Vorinostat

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

Beta-catenin status in paediatric medulloblastomas: correlation of immunohistochemical expression with mutational status, genetic profiles, and clinical characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

Agonists of an ecdysone-inducible mammalian expression system inhibit Fas Ligand- and TRAIL-induced apoptosis in the human colon carcinoma cell line RKO.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

A phase I, pharmacokinetic, and pharmacodynamic study of two schedules of vorinostat in combination with 5-fluorouracil and leucovorin in patients with refractory solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

MYC family amplification and clinical risk-factors interact to predict an extremely poor prognosis in childhood medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

Large cell/anaplastic medulloblastoma: outcome according to myc status, histopathological, and clinical risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

A mouse model of the most aggressive subgroup of human medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

An animal model of MYC-driven medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

Global gene expression profiling confirms the molecular fidelity of primary tumor-based orthotopic xenograft mouse models of medulloblastoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

p53 expression predicts dismal outcome for medulloblastoma patients with metastatic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

A clinicobiological model predicting survival in medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

Intense p53 staining is a valuable prognostic indicator for poor prognosis in medulloblastoma/central nervous system primitive neuroectodermal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

Pharmacological activation of the p53 pathway by nutlin-3 exerts anti-tumoral effects in medulloblastomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

Histone deacetylase inhibitors prime medulloblastoma cells for chemotherapy-induced apoptosis by enhancing p53-dependent Bax activation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

Inhibitors of histone deacetylases as potential therapeutic tools for high-risk embryonal tumors of the nervous system of childhood

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

HKI 46F08, a novel potent histone deacetylase inhibitor, exhibits antitumoral activity against embryonic childhood cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

Reports from the 2010 Clinical and Translational Cancer Research Think Tank meeting: design strategies for personalized therapy trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

HDAC family: What are the cancer relevant targets?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

Class I histone deacetylase expression has independent prognostic impact in human colorectal cancer: specific role of class I histone deacetylases in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

Response of preclinical medulloblastoma models to combination therapy with 13-cis retinoic acid and suberoylanilide hydroxamic acid (SAHA).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

Enhancement of radiation response in osteosarcoma and rhabdomyosarcoma cell lines by histone deacetylase inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

Histone deacetylase inhibitors sensitize human non-small cell lung cancer cells to ionizing radiation through acetyl p53-mediated c-myc down-regulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

Low-dose valproic acid enhances radiosensitivity of prostate cancer through acetylated p53-dependent modulation of mitochondrial membrane potential and apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

HDAC inhibitor, valproic acid, induces p53-dependent radiosensitization of colon cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11060-012-0978-1

Histone deacetylase inhibitors valproic acid and depsipeptide sensitize retinoblastoma cells to radiotherapy by increasing H2AX phosphorylation and p53 acetylation-phosphorylation.

21 January 2018

1 reference

12 December 2020

CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors

1 reference

12 December 2020

MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors

1 reference

12 December 2020

Histone deacetylase inhibitors induce cell death and enhance the susceptibility to ionizing radiation, etoposide, and TRAIL in medulloblastoma cells.

1 reference

12 December 2020

TM4: a free, open-source system for microarray data management and analysis

1 reference

12 December 2020

Histone deacetylase inhibitors, but not vincristine, cooperate with radiotherapy to induce cell death in medulloblastoma.

1 reference

12 December 2020

10.1007/S11060-012-0978-1

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23054560%20AND%20SRC:MED&resulttype=core&format=json

10 March 2020

1 reference